Skip to main content
TME Pharma N.V. logo

TME Pharma N.V. — Investor Relations & Filings

Ticker · ALTME ISIN · NL0015000YE1 LEI · 724500EPNADXWZ58U595 Euronext Growth Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2025-10-30 Report Publication Anno…
Country NL Netherlands
Listing Euronext Growth ALTME

About TME Pharma N.V.

https://www.tmepharma.com/

TME Pharma N.V. is a clinical-stage biotechnology company developing novel therapies for aggressive cancers by targeting the tumor microenvironment (TME). The company's proprietary technology focuses on neutralizing chemokines within the TME to break down the tumor's protective barriers and inhibit its repair mechanisms. This approach is designed to work in combination with other treatments, such as radiotherapy and immunotherapy, to enhance their therapeutic impact. TME Pharma's lead clinical programs are concentrated on difficult-to-treat cancers, including glioblastoma and pancreatic cancer. Its lead candidate, NOX-A12, has shown promising results in clinical trials for glioblastoma, demonstrating a statistically significant improvement in patient survival when combined with standard-of-care therapies.

Recent filings

Filing Released Lang Actions
TME Pharma publishes its semi annual results and half-year report
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the publication of TME Pharma's semi-annual results and half-year report. While it contains some summary financial figures (turnover, net loss, cash position), it explicitly states that the full semi-annual report is available on the company's website, indicating this document is an announcement rather than the full report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). H1 2025
2025-10-30 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release from TME Pharma that serves two primary purposes: announcing the date for the publication of upcoming half-year results (Report Publication Announcement) and disclosing a share purchase by the CEO (Director's Dealing). According to the classification hierarchy, when a document contains multiple distinct regulatory disclosures, the most specific and actionable financial event takes precedence. The CEO's share purchase is a formal 'Director's Dealing' (DIRS) notification, which is a high-priority regulatory disclosure. While it also contains an RPA component, the DIRS content is the core regulatory event being reported.
2025-09-22 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 95% confidence The document is a press release from TME Pharma that serves two primary purposes: announcing the date of the upcoming interim results publication and reporting a director's share acquisition (insider dealing). While it contains elements of a report publication announcement (RPA) and director's dealing (DIRS), the document is primarily a regulatory announcement (RNS) that bundles these corporate updates. Given the 'Regulatory Filings' category is the designated fallback for miscellaneous announcements that do not fit a single specific category perfectly, and this document covers multiple distinct topics (financial calendar and insider trading), RNS is the most appropriate classification.
2025-09-22 French
Inside Information: Other news releases
Capital/Financing Update Classification · 95% confidence The document is a press release from TME Pharma announcing the completion of a financing transaction and providing an update on the company's cash position. It details the receipt of funds, the current cash balance, and strategic operational updates. This falls under the category of capital and financing updates as it directly relates to the company's fundraising activities and capital structure.
2025-09-01 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 95% confidence The document is a press release from TME Pharma announcing the finalization of a fundraising operation and providing an update on the company's cash position. It details the amount raised, the current cash balance, and strategic updates regarding the company's business model and investment strategy. Since this is an announcement regarding financing activities and capital structure, it falls under the 'Capital/Financing Update' category.
2025-09-01 French
Inside Information / Other news releases
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding a new bond issuance and capital raising activity by TME Pharma. It outlines the terms of the debt, the issuance of warrants, the use of proceeds, and the participation of management. It is not a report publication announcement (RPA) because it contains the primary details of the transaction itself rather than just announcing the availability of a separate report. It fits the definition of a Capital/Financing Update (CAP) as it details fundraising and capital structure changes.
2025-08-25 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.